Biological agents that target VEGF or EGFR are often used in conjunction with other chemotherapies to treat metastatic colorectal carcinoma (CRC).
Studies attempting to link ASA to a reduction in the risk of CRC have had mixed results.
Results from a safety lead-in phase conducted prior to a phase 3 trial examining the safety and tolerability of encorafenib, binimetinib, and cetuximab in combination led the FDA to assign the regimen a breakthrough therapy designation.
The vitamin D response element plays a direct role in regulating gene expression, a potential mechanism to explain how vitamin D is involved with malignancy.
The FDA based its approval on evidence from the ongoing, non-randomized CheckMate-142 phase 2 study, for which researchers treated 119 patients with nivolumab plus ipilimumab.
A Merck-funded study examines survival data on patients with metastatic colorectal cancer; results were presented during ESMO 2018.
Atezolizumab, Cobimetinib Combination Failed to Improve Survival Versus Regorafenib in Relapsed Colorectal CancerJune 27, 2018
The IMblaze370 trial did not meet the primary endpoint.
CORRECT and CONCUR trials demonstrated an improvement in OS for patients receiving regorafenib compared with placebo.
Researchers sought to determine if autophagy-related proteins are associated with survival among patients with CRC.
Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic SitesJune 22, 2018
In patients with colorectal cancer, rectal tumors and lung metastasis appeared to be linked to an elevated risk for brain cancer.
The CRICKET trial is evaluating the third-line retreatment of patients with mCRC with cetixumab plus irinotecan.
Increasing the sensitivity cutoff from 5% to 1% in next-generation sequencing allowed for the identification of 28% more RAS/BRAF mutations.
The OncoBEAM RAS kit for circulating tumor DNA (ctDNA) analysis of patients with metastatic colorectal cancer (mCRC) demonstrated high positive and negative agreement of RAS mutations detected by tumor tissue analysis.
In this randomized screening trial, patients with advanced adenomas detected by flex sigmoidoscopy (FSG) were at significantly increased risk of CRC compared to those with no adenomas.
BEACON CRC Safety Lead-in Study suggests safety and efficacy of triplet combination therapy for treatment of metastatic colorectal cancerApril 13, 2018
Preliminary analysis of the Safety Lead-in Study for the BEACON CRC reveals that the triplet combination is generally well tolerated and has promising clinical activity with an overall response rate of 41%.
The authors of this study at Wake Forest School of Medicine aimed to evaluate whether utilizing an iPad app as a digital health intervention could result in higher screening rates for CRC.
Colorectal cancer (CRC) screening serves as a critical element of CRC prevention and management. To date, colonoscopy remains the gold standard with respect to CRC screening in the United States.
Colonic stenting can be used as a temporizing measure to help bridge the patient to surgery for optimal timing.
The purpose of this trial was to determine the efficacy and safety of mXELIRI as a second-line therapy for CRC in an Asian population.
Nut intake is associated with a reduced risk of type 2 diabetes and insulin resistance.
Researchers randomly assigned 143 patients to receive cetuximab plus mFOLFOXIRI followed by cetuximab or bevacizumab maintenance.
Preclinical studies demonstrated that napabucasin — a first-in-class cancer stemness inhibitor that blocks STAT3 — may prevent self-renewal and induce cancer stem cell death.
Current screening methods have a low sensitivity for precancerous lesions and are inconvenient, leading to high rates of noncompliance.
Researchers treated 74 patients with dMMR/MSI-H mCRC with nivolumab 3 mg/kg every 2 weeks.
MEK inhibition with cobimetinib may improve the response rate with checkpoint inhibition.
Survivors assigned to an experimental arm showed an improvement in the FACT-C functional well-being sub-scale from baseline to 12 weeks.
Researchers evaluated the outcomes of 453 patients with stage I to III esophageal cancer who received definitive or preoperative chemoradiation.
After median follow-up of 2.4 and 2.9 years for women who initiated AIs and tamoxifen, respectively, no increased risk of colorectal cancer was observed among women treated with AIs.
Evidence suggests that microbiota dysbiosis occurs among patients with cancer, particularly those with cancers of the digestive tract.
While colonoscopy is considered the gold standard screening method for CRC, it can be burdensome to patients; blood tests, while less burdensome, are not necessarily as sensitive.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib